The source of peptides that enter the major histocompatibility class I (MHCI) pathway has been intensively debated over the last two decades. The initial assumption that peptides are derived from degradation of full length proteins was challenged by a model in which alternative translation products are a source of peptides. This model has been tested and supported by scientific data. We now need new hypotheses on the physiological implications of different sources of peptides for the MHCI pathway. The aim of this overview is to give an up-to-date account of the source of antigenic peptide material for the MHCI pathway and to incorporate the more recent observations of alternative mRNA translation products into existing models of the direct and cross-presentation pathways.

Equipe Labellisée la Ligue Contre le Cancer Inserm UMR1162 Université Paris 7 Institut de Génétique Moléculaire 27 rue Juliette Dodu 75010 Paris France

Equipe Labellisée la Ligue Contre le Cancer Inserm UMR1162 Université Paris 7 Institut de Génétique Moléculaire 27 rue Juliette Dodu 75010 Paris France; RECAMO Masaryk Memorial Cancer Institute Zluty kopec 7 656 53 Brno Czech Republic; Department of Medical Biosciences Umeå University SE 90185 Umeå Sweden

Institut Gustave Roussy Université Paris Sud Unité 1015 département d'immunologie 114 rue Edouard Vaillant 94805 Villejuif France

Citace poskytuje Crossref.org

Nuclear processing of nascent transcripts determines synthesis of full-length proteins and antigenic peptides